

## Measurement verification in the clinical laboratory:

**A guide to assessing analytical performance during the acceptance testing of methods (quantitative examination procedures) and/or analysers**

Zahra Khatami<sup>1</sup>, Robert Hill<sup>2</sup>, Catherine Sturgeon<sup>3</sup>, Edward Kearney<sup>4</sup>, Peter Breadon<sup>5</sup>  
Anders Kallner<sup>6</sup>

<sup>1</sup> Department of Clinical Biochemistry, Queen's Hospital Romford, <sup>2</sup> Department of Clinical Biochemistry, King's Mill Hospital, Sutton-in-Ashfield, <sup>3</sup> Department of Clinical Biochemistry, Edinburgh Royal Infirmary <sup>4</sup> Department of Clinical Biochemistry, Queen Elizabeth The Queen Mother Hospital, Margate, <sup>5</sup> Department of Clinical Biochemistry, Southport and Ormskirk Hospitals, <sup>6</sup> Department of Clinical Chemistry Karolinska University Hospital, Stockholm, Sweden,

**This paper and the associated spreadsheets, background statistical notes and worked examples were commissioned by the Scientific Committee of the Association for Clinical Biochemistry. Anders Kallner represented the Nordic Association for Clinical Chemistry. Peter Breadon represented the Institute of Biomedical Sciences.**

## Contents

1. Aims.....	2
2. Scope.....	2
3. Definition of verification .....	2
4. Assumptions.....	2
5. Assessing imprecision.....	3
5.1 Choice of procedure and material .....	3
5.2 Procedure for assessing imprecision.....	3
6. Assessing bias .....	4
6.1 Specific procedure for assessing bias using patient samples.....	4
6.2 Specific procedures for assessing bias using reference material with an assigned value.....	5
6.3 Specific procedure for assessing bias using material from EQA schemes .....	5
7. Instrument dilution check .....	5
7.1 Procedure .....	6
8. Glossary .....	6
9. Acknowledgements.....	8
10. References.....	9

Key words: Quality assessment, patient safety, procurement, measurement system, instrument, precision, trueness, dilution, clinical laboratory, guidance.

## 1. Aims

- 1.1 Provide practical recommendations on the minimum requirements for the verification of analytical performance when introducing new methods and/or analysers into a clinical laboratory, i.e. to ensure that performance meets the quality specifications set by the laboratory during procurement.
- 1.2 Ensure patient safety by verifying analytical performance.

## 2. Scope

1. Experimental confirmation of the key analytical components of measurement uncertainty, i.e. precision, trueness {1} and linearity of dilution.
2. Comparison of manufacturers' performance claims with data collected in the laboratory.
3. An assessment of the laboratory and clinical implications of estimated bias upon reference intervals and measurements in serially monitored patients.
4. A consideration of the uncertainties associated with pre- and post-analytical procedures has not been included.
5. The procedures below cannot be used to verify ordinal (semi-quantitative) or dichotomous results.

## 3. Definition of verification

The generic definition of verification is: 'provision of objective evidence that a given item fulfils specified requirements' {1}.

In this document 'verification' is used to describe the experimental confirmation of performance specifications by the user. This usually includes an assessment trueness (bias) and precision (imprecision) in the context of the intended use.

In Europe it is the statutory responsibility of the manufacturer to determine, describe and verify the performance of the measuring system (EU IVD Directive 98/79 {2})

## 4. Assumptions

1. Verification is a responsibility of the laboratory director who must ensure that it is completed in a timely manner within available resources (i.e. time and expertise).
2. An understanding of the measurement uncertainty {3, 4} (e.g. within and between measurement results) of any laboratory result is essential for the interpretation of results.
3. The performance specifications set by the user in the tendering specification are met by the manufacturer in their performance claims.
4. The performance claims made by the manufacturer were obtained on a comparable instrument and that any modifications to the measurement system since the establishment of the performance claims are stated.
5. The manufacturer will supply, on demand, the results and the experimental design used in the studies to formulate their performance claims.

6. Where relevant, the following data has been made available: Analytical sensitivity, specificity, detection limit, measurement interval, linearity, effect of interferences including hooking and sample carry-over, and uncertainty profile.
7. Performance claims by the manufacturer should be determined using procedures recognised by appropriate regulatory bodies (e.g. ISO, CEN, IFCC, or CLSI standards). These procedures usually take more variables into consideration than verification by the laboratory. For example, if the CLSI EP5 guideline is followed by the manufacturer, it would be expected that the imprecision estimated in the laboratory during its verification would be smaller than that claimed by the manufacturer. If other procedures have been used for verification, the experimental design must be fully described.
8. Staff training and familiarisation with the new measurement system has been completed.
9. Laboratory infrastructure (e.g. interfacing, electrical connections, air conditioning, UPS support, etc) is adequate.
10. Health and Safety requirements have been met.

*The procedures described in this document may not be sufficient to establish that a measuring system is fit for purpose in the clinical context for which it is intended.*

## **5. Assessing imprecision**

### **5.1 Choice of procedure and material**

An experimental design and statistical approach that is comparable to that used by the manufacturer should be chosen to allow a realistic verification of the manufacturer's claims. Either patient pooled samples or reference materials may be used. If reference materials are used it is assumed that commutability between the reference material and patient material has been demonstrated and documented by the manufacturer.

Where the medical decision point is close to the detection limit (e.g. Troponin, TSH or PSA) then pooled patient samples must be used.

#### *Patient samples*

Pooled samples are prepared at two or more clinically relevant concentrations. All samples containing those interfering substances identified by the manufacturer e.g. drug metabolites, haemolysis, should be excluded. For stored samples, if the manufacturer's instructions and the stability of the measurand allow, refrigeration is the preferred method of storage to avoid artefacts introduced in the freeze-thaw cycle such as particulate matter.

#### *Reference material*

Reference material e.g. IQC material should be chosen at two or more clinically relevant concentrations.

### **5.2 Procedure for assessing imprecision**

Before commencing verification ensure satisfactory calibration of the measurement system and ensure that reagents are within their expiry date.

1. Measure the concentration of one series of samples per day for a minimum of five days. The series must consist of five replicate samples at two or more concentrations. It is preferable to sample from five separate cups of the same material. If a series must be rejected because of operating difficulties, record the circumstances, discard the data,

- and conduct a further additional series. **Note:** It is advised that sufficient pooled and aliquotted material is prepared for each concentration.
2. The analytical conditions (e.g. reagent or calibrator lot) may be held constant or varied between series to simulate normal operating procedures. When imprecision is estimated between series under varying analytical conditions it is referred to as “intermediate imprecision” for the purpose of this paper.
  3. Estimate the within and between series imprecision using analysis of variance (ANOVA). The spreadsheet provides a summary of the components of variation in terms of mean, standard deviation and coefficient of variation. [Spreadsheet A](#) is designed to calculate the imprecision, compare it with claims of the manufacturer and determine whether they are statistically comparable. Note that the manufacturer’s claims may be based on more extensive studies e.g. CLSI EP-5 guideline.

## 6. Assessing bias

Bias should be estimated as part of the verification process and assessed with patient-based material. Bias should also be determined using a reference material with a traceable assigned value or against a peer group of laboratories using the same method or group of methods.

### 6.1 Specific procedure for assessing bias using patient samples

Measurement of the bias against the previous or alternative laboratory method should be undertaken using paired patient comparisons. This approach is only comparative and provides no information about whether either method is biased against the appropriate reference method.

1. Obtain at least 20 patient samples at clinically relevant concentrations within the measuring interval of the method. All samples containing those known interfering substances identified by the manufacturer (e.g. drug metabolites, haemolysis) should be excluded.
2. Measure the concentrations of the samples, preferably in duplicate, using both the test and comparative procedures. Measurement of paired samples should be performed within a short time interval taking into account the stability of the measurand under the storage conditions used. It is preferable to use separate sample cups for each replicate rather than allowing the instrument to sample twice from the same cup.
3. Where duplicates have been measured, their mean should be used for comparison purposes.
4. Construct a difference graph to illustrate the difference between methods.
5. Calculate whether there is a statistically significant difference between the methods by evaluating the  $\chi^2$ . The difference graph and the statistical procedure are provided in [spreadsheet B](#).
6. If a significant bias has been demonstrated, estimate its clinical significance at appropriate decision levels.
7. A clinically significant bias should be confirmed by;
  - a. Obtaining additional patient comparison data from other users or the manufacturer.
  - b. An extended study of 40 samples measured in duplicate {5}

Information from 7a) and 7b) can be used to decide whether amendments of reference intervals will be necessary.

## 6.2 Specific procedures for assessing bias using reference material with an assigned value.

For each selected concentration of reference material, the results of the laboratory's measurements must be compared with the assigned value and its uncertainty. At least two different concentrations should be studied and preferably chosen close to medical decision points.

1. Measure the concentration of the analyte (component) under investigation in duplicate on three to five different occasions.
2. Calculate the mean and standard deviation of all measurements.
3. Compare with the reference value of the material and estimate the bias.
4. Evaluate the significance of difference by Student's t-statistics see [spreadsheet C](#) {6}.

### 6.2.b Practical points

Commutable certified reference materials are available for a limited number of analytes (e.g. CRM 470 for proteins). The Joint Committee for Traceability in Laboratory Medicine (JCTLM) {7} maintains a list of materials that are available and may be obtained from NIBSC {8}, IRMM {9} etc. Some companies may provide similar materials that are not certified but have a nominal assigned value and uncertainty.

## 6.3 Specific procedure for assessing bias using material from EQA schemes

Bias can be estimated by measuring the concentration of relevant analytes present in EQA materials. **Note** EQA samples may not always be commutable with clinical samples (e.g. matrix effects). The EQA target value used is the consensus peer group mean value.

1. Measure the concentration of the analytes under investigation in 7 to 10 EQA samples of different concentrations in duplicate.
2. Estimate the significance of the bias by calculating the difference between the peer group method mean of the EQA material and the mean of the results as measured in the laboratory. ([Spreadsheet D](#))

### 6.3.b Practical points

Previously circulated EQA samples and their associated reports may be obtained from EQA providers. A representative mean, the standard error of the mean and a description of the methods used should be supplied.

## 7. Instrument dilution check

Confirmation of linearity of a method is not a requirement of verification. However, it is advisable to confirm that an accurate procedure is available for diluting samples that fall above the measurement interval i.e. beyond the concentration at which the manufacturer recommends measurement without dilution. This is particularly important for measurands which occasionally exceed the measuring interval e.g. hormones, tumour markers and enzymes.

Non-linearity may indicate gross errors due to incorrect software settings, malfunction in fluid handling or the use of inappropriate diluents. The following procedure tests the dilution performed by an instrument under routine conditions. It assumes that the linearity of the chemistry within the measurement interval has been established by the manufacturer.

## 7.1 Procedure

1. Identify a patient sample with a high concentration of measurand i.e. higher than the threshold above which the manufacturer recommends dilution but below the threshold above which the 'hook effect' is known to occur.
2. Set the instrument to make three different dilutions, of the same sample and measure the concentration in duplicate.
3. Using calibrated pipettes and the manufacturer's recommended diluent, simulate the instrument dilutions. Note calibrated pipettes used for transfer of volumes of less than 25 µL may introduce significant uncertainty to the manual dilution.
4. Measure the concentration of the manually diluted sample in duplicate using the procedure recommended by the manufacturer.
5. Defining the manual dilution as the 'expected' concentration and the instrument dilution as the 'observed' concentration, compare the difference between the two means at each level where X is the concentration of the substance:  

$$\%difference = \frac{ExpectedX - ObservedX}{ExpectedX} \times 100$$
6. If the means are not within 15 % of each other, investigate the cause and repeat if necessary. Discuss results with the manufacturer if appropriate.

### 7.1.b Practical Points

If no suitable patient samples are available during the verification period, this procedure may be delayed until such a sample is encountered during routine operation.

## 8. Glossary

analyte, substance or chemical whose concentration is measured in an analytical procedure  
 This term has been superseded by 'component' (defined below) but is used in this document to simplify the language of metrology.

**analytical sensitivity**, quotient of the change in an indication of a measuring system and the corresponding change in a value of a quantity being measured VIM 07, § 4.12

**analytical specificity** ability of a measuring system, using a specified measurement procedure to determine solely the measurand.

**between series precision** - see intermediate precision

**certified reference material (CRM)**, reference material accompanied by documentation issued by an authoritative body and providing one or more specified property values with associated uncertainties and traceability, using valid procedures VIM 07, § 5.,14

**commutability of a reference material**, property of a reference material, demonstrated by the closeness of agreement between the relation among the measurement results for a stated quantity in this material, obtained according to two given measurement procedures, and the relation obtained among the measurement results for other specified materials VIM 07, § 5.15

**component**, definable part of a system {10}

**definitional uncertainty**, component of measurement uncertainty resulting from the finite amount of detail in the definition of a measurand VIM 07, § 2.27

**detection limit**, the minimum single result with a stated probability that can be distinguished from a suitable blank value . The limit defines the point at which analysis becomes possible and this may be different from the lower limit of determinable analytical interval. {11}

**Hook effect**, falsely low values on an immunoassay when an overwhelming amount of antigen affects the binding capacity of the added antibody; especially when testing for thyroglobulin in management of thyroid cancer  
<http://www.medilexicon.com/medicaldictionary.php?t=28026> (accessed 090603)

**intermediate precision** (intermediate measurement precision//intermediate precision) - measurement precision under a set of intermediate precision conditions of measurement. VIM 07, § 2.23

**intermediate precision conditions of measurement** (intermediate precision condition), condition of measurement, out of a set of conditions that includes the same measurement procedure, same location, and replicate measurements on the same or similar objects over an extended period of time, but may include other conditions involving changes; VIM 07, § 2.22

**matrix effect**, the combined effect of all components of a sample other than the analyte on the measurement of the quantity of interest. If a specific component can be identified as causing an effect then this is referred to as interference. {11}

**measurand**, quantity intended to be measured VIM 07, § 2.3

**measurement bias** - estimate of a systematic measurement error. VIM 07, § 2.18

**measurement procedure**, detailed description of a measurement according to one or more measurement principles and to a given measurement method, based on a measurement model and including any calculation to obtain a measurement result; VIM 07, § 2.6

**measurement uncertainty**, non-negative parameter characterizing the dispersion of the quantity values being attributed to a measurand, based on the information used; VIM 07, § 2.26

**measuring interval**, set of values of quantities of the same kind that can be measured by a given measuring instrument or measuring system with specified instrumental uncertainty, under defined conditions; VIM 07, § 4.7

**measuring system** set of one or more measuring instruments and often other devices, including any reagent and used to generate measured quantity values within specified intervals for quantities of specified kinds. NOTE A measuring system may consist of only one measuring instrument VIM 07, § 3.2

**precision**, closeness of agreement between indications or measured quantity values obtained by replicate measurements on the same or similar objects under specified conditions; VIM 07, § 2.15

**reference material**, material, sufficiently homogeneous and stable with reference to specified properties, which has been established to be fit for its intended use in measurement or in examination of nominal properties VIM 07, § 5.13

**repeatability** (measurement repeatability, repeatability), measurement precision under a set of repeatability conditions of measurement VIM 07, § 2.21

**sample carry-over**, carry over from a preceding sample probe into a following specimen cup which will influence the result {11}

**traceability**, property of a measurement result whereby the result can be related to a reference through a documented unbroken chain of calibrations, each contributing to the measurement uncertainty; VIM 07, § 2.41

**trueness**, closeness of agreement between the average of an infinite number of replicate measured quantity values and a reference quantity value; VIM 07, § 2.14

**uncertainty profile**, absolute or relative uncertainty estimated at different concentrations within a measuring interval

**verification**, provision of objective evidence that a given item fulfils specified requirements. In the context of this document confirmation that performance properties of a measuring system are achieved. VIM 07, § 2.44

**VIM**, international vocabulary of metrology – see reference 1

**within series precision** - see repeatability

## 9. Acknowledgements

The encouragement and help in defining the scope for this paper from Gordon Avery (Abbott Diagnostics and Poly Gerondaes (Ortho Clinical Diagnostics) is acknowledged. They also provided constructive criticism of the drafts.

The authors are also grateful to Graham White (Adelaide, Australia) and Sophie Barnes (London UK) for comments on early drafts of this document

## 10. References

1. International vocabulary of metrology — Basic and general concepts and associated terms (VIM) JCGM 200:2008. VIM 07, Geneva 2008. [http://www.bipm.org/utis/common/documents/jcgm/JCGM\\_200\\_2008.pdf](http://www.bipm.org/utis/common/documents/jcgm/JCGM_200_2008.pdf) (accessed 090603).
2. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices Official Journal 1998;41:L331. <http://eur-lex.europa.eu> (accessed 090603).
3. Guide to the expression of Uncertainty in Measurements. ISO, Geneva 1993. <http://www.bipm.org/en/publications/guides/gum.html> (accessed 090603).
4. Quantifying Uncertainty in analytical measurement, Eurachem/Citac [www.eurachem.org](http://www.eurachem.org) (accessed 090603).
5. Clinical and Laboratory Standards Institute (CLSI). Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Second Edition. CLSI document EP9-A2 (ISBN 1-56238-472-4). Wayne, Pennsylvania 19087-1898 USA, 2002.
6. Clinical and Laboratory Standards Institute (CLSI). User Verification of Performance for Precision and Trueness; Approved Guideline—Second Edition. CLSI document EP15-A2 (ISBN 1-56238-574-7). Wayne, Pennsylvania 19087-1898 USA, 2005.
7. Joint Committee for Traceability in Laboratory Medicine (JCTLM). <http://www.bipm.org/en/committees/jc/jctlm/> (accessed 090603)
8. National Institute for Biological Standards and Control (NIBSC) <http://www.nibsc.ac.uk/products/directorylist.asp> (accessed 090603) .
9. Institute for Reference Materials and Measurements (IRMM). <http://irmm.jrc.ec.europa.eu/html/homepage.htm>(accessed 090603)
10. Compendium of Chemical Terminology. IUPAC 2006. [www.goldbook.iupac.org](http://www.goldbook.iupac.org) (accessed 090603).
11. Dybkaer R. Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine. Clin Chem Clin Biochem 1997;35(2):141-173.

Document date 090605

Review date 100605